Analysen von Richard Vosser
| 07.11.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 05.11.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 03.11.25 | Merck Overweight | JP Morgan Chase & Co. | |
| 03.11.25 | Roche Underweight | JP Morgan Chase & Co. | |
| 30.10.25 | Merck Overweight | JP Morgan Chase & Co. | |
| 30.10.25 | Bayer Neutral | JP Morgan Chase & Co. | |
| 29.10.25 | Merck Overweight | JP Morgan Chase & Co. | |
| 28.10.25 | Novartis Neutral | JP Morgan Chase & Co. | |
|
Werbung
|
|||
| 27.10.25 | Roche Underweight | JP Morgan Chase & Co. | |
| 24.10.25 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 24.10.25 | Sanofi Overweight | JP Morgan Chase & Co. | |
| 23.10.25 | Roche Underweight | JP Morgan Chase & Co. | |
| 22.10.25 | Sanofi Overweight | JP Morgan Chase & Co. | |
| 20.10.25 | Novartis Neutral | JP Morgan Chase & Co. | |
| 20.10.25 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 20.10.25 | Roche Underweight | JP Morgan Chase & Co. | |
| 17.10.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 17.10.25 | Sartorius vz. Overweight | JP Morgan Chase & Co. | |
| 17.10.25 | Merck Overweight | JP Morgan Chase & Co. | |
| 16.10.25 | Merck Overweight | JP Morgan Chase & Co. | |
| 16.10.25 | Sartorius Stedim Biotech Overweight | JP Morgan Chase & Co. | |
| 16.10.25 | Sartorius vz. Overweight | JP Morgan Chase & Co. | |
| 15.10.25 | Sanofi Overweight | JP Morgan Chase & Co. | |
| 13.10.25 | Roche Underweight | JP Morgan Chase & Co. | |
| 13.10.25 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 09.10.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 08.10.25 | Roche Underweight | JP Morgan Chase & Co. | |
| 07.10.25 | Roche Underweight | JP Morgan Chase & Co. | |
| 07.10.25 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 06.10.25 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 06.10.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 30.09.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 29.09.25 | Roche Underweight | JP Morgan Chase & Co. | |
| 29.09.25 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 25.09.25 | Merck Overweight | JP Morgan Chase & Co. | |
| 25.09.25 | Sanofi Overweight | JP Morgan Chase & Co. | |
| 23.09.25 | Roche Underweight | JP Morgan Chase & Co. | |
| 22.09.25 | Sanofi Overweight | JP Morgan Chase & Co. | |
| 22.09.25 | Roche Underweight | JP Morgan Chase & Co. | |
| 19.09.25 | Sartorius vz. Overweight | JP Morgan Chase & Co. | |
| 18.09.25 | Roche Underweight | JP Morgan Chase & Co. | |
| 18.09.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 17.09.25 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 17.09.25 | Sanofi Overweight | JP Morgan Chase & Co. | |
| 11.09.25 | Sanofi Overweight | JP Morgan Chase & Co. | |
| 10.09.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 09.09.25 | Novartis Neutral | JP Morgan Chase & Co. | |
| 04.09.25 | Sanofi Overweight | JP Morgan Chase & Co. | |
| 04.09.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 01.09.25 | Roche Underweight | JP Morgan Chase & Co. | |